All lobbying filings

FORBES-TATE

Lobbying for ALEXION PHARMACEUTICALS, INC. · Biopharmaceutical Company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Massachusetts · House · Senate · $50,000.00 income · posted Apr 18, 2025

Official filing document

Bills named in this filing 2

HR 5539
ORPHAN Cures Act
S 3131
ORPHAN Cures Act

Lobbying activity 2

Medicare/Medicaid

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).

Health Issues

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to H.R 5539/S. 3131 - the ORPHAN Cures Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.